The Experts below are selected from a list of 747 Experts worldwide ranked by ideXlab platform

Sungkee Chung - One of the best experts on this subject based on the ideXlab platform.

Kyongtai Kim - One of the best experts on this subject based on the ideXlab platform.

  • A guanidine-appended scyllo-Inositol Derivative AAD-66 enhances brain delivery and ameliorates Alzheimer's phenotypes
    Scientific reports, 2017
    Co-Authors: Dohyun Lee, Kyongtai Kim, Woo-sirl Lee, Sungsu Lim, Yun Kyung Kim, Hoe-yune Jung, Sanket Das, Juhyun Lee, Wenjie Luo, Sungkee Chung
    Abstract:

    Alzheimer’s disease (AD) is a degenerative brain disease that destroys memory and other important mental functions but lacks efficient therapeutic agents. Blocking toxic amyloid β (Aβ) could be beneficial for AD and represents a promising therapeutic strategy for AD treatment. scyllo-Inositol (SI) is a potential therapeutic for AD by directly interacting with the Aβ peptide to inhibit Aβ42 fiber formation. Clinical studies of SI showed promising benefits on mild to moderate AD, however, with limitations on dosage regime. A new strategy to enhance the brain delivery of SI is needed to achieve the efficacy with minimum adverse effects. Herein, we report that a novel guanidine-appended SI Derivative AAD-66 resulted in more effective reductions of brain Aβ and plaque deposits, gliosis, and behavioral memory deficits in the disease-established 5xFAD mice. Overall, our present study reveals the potential of AAD-66 as a promising therapeutic agent for AD.

  • A guanidine-appended scyllo-Inositol Derivative AAD-66 enhances brain delivery and ameliorates Alzheimer’s phenotypes
    Nature Publishing Group, 2017
    Co-Authors: Dohyun Lee, Kyongtai Kim, Woo-sirl Lee, Sungsu Lim, Yun Kyung Kim, Hoe-yune Jung, Sanket Das, Juhyun Lee, Wenjie Luo, Sungkee Chung
    Abstract:

    Abstract Alzheimer’s disease (AD) is a degenerative brain disease that destroys memory and other important mental functions but lacks efficient therapeutic agents. Blocking toxic amyloid β (Aβ) could be beneficial for AD and represents a promising therapeutic strategy for AD treatment. scyllo-Inositol (SI) is a potential therapeutic for AD by directly interacting with the Aβ peptide to inhibit Aβ42 fiber formation. Clinical studies of SI showed promising benefits on mild to moderate AD, however, with limitations on dosage regime. A new strategy to enhance the brain delivery of SI is needed to achieve the efficacy with minimum adverse effects. Herein, we report that a novel guanidine-appended SI Derivative AAD-66 resulted in more effective reductions of brain Aβ and plaque deposits, gliosis, and behavioral memory deficits in the disease-established 5xFAD mice. Overall, our present study reveals the potential of AAD-66 as a promising therapeutic agent for AD

  • syntheses of d and l myo Inositol 1 2 4 5 tetrakisphosphate and stereoselectivity of the i 1 4 5 p3 receptor binding
    Bioorganic & Medicinal Chemistry Letters, 1998
    Co-Authors: Sungkee Chung, Boogyo Shin, Youngtae Chang, Byungchang Suh, Kyongtai Kim
    Abstract:

    D- and L-myo-Inositol 1,2,4,5-tetrakisphosphate [D- & L-I(1,2,4,5)P4], which are analogues of D-myo-Inositol 1,4,5-trisphosphate [D-I(1,4,5)P3], a calcium mobilizing second messenger, were synthesized via resolution of the camphanate ester of a myo-Inositol Derivative, and the binding affinities to I(1,4,5)P3 receptor were measured.

Reinhard Hensel - One of the best experts on this subject based on the ideXlab platform.

Yutaka Watanabe - One of the best experts on this subject based on the ideXlab platform.

Stefan Scholz - One of the best experts on this subject based on the ideXlab platform.